In the past five months, rupee has depreciated by 10-11%, benefitting exporting pharma companies in terms of better sales realisation and profitability. Hence, we have revised our INR assumptions to Rs. 69 vs. earlier Rs. 67 (for FY2020E and FY2021E), leading to upgrade of 2-3% each in our sales and earnings estimates (FY2020E and FY2021E) for Divis Laboratories
Disclaimer: The views and stock ideas expressed by members on stockadda.com are their own, and not that of the website or its management.The views and stock ideas are for informational purposes only and should not be construed to be recommendations to buy or sell any securities.Stockadda.com advises members to check & consult with certified experts before taking any investment decisions.
535 Investors Online.